An excellent question.
The new guidelines are interesting. They expand the options that are considered preferred, especially among protease inhibitors. Now, in addition to Kaletra, ritonavir boosted fosamprenavir and atazanavir are considered preferred. Also, there is no longer the qualification regarding tenofovir and Kaletra. Either tenofovir + FTC or Combivir are considered fine to couple with efavirenz or one of the three boosted PIs.
These revisions reflect the findings of major clinical trials and also common practice. As such, I like the changes. There are some excellent studies (described throughout this website) comparing many of the preferred regimens. Thus, the clinician has fairly good data with which to make a decision reagrding the best therapy for a particular patient.
The guidelines make an excellent read, are thoughtfully considered and really are worth reviewing.
Thanks for asking, DW
